Leflunomide Ratiopharm

Leflunomide, the active ingredient in Leflunomide Ratiopharm, is a disease-modifying antirheumatic drug presented as an oral tablet for oral use. It is indicated for the treatment of rheumatoid arthritis and psoriatic arthritis in adult patients, helping to reduce inflammation and slow joint damage.

GNH USA supplies Leflunomide Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution across multiple continents and regulatory compliance.

Leflunomide is a disease-modifying antirheumatic drug that targets inflammatory pathways in rheumatic diseases.

Rheumatoid arthritis: reduces joint inflammation, pain and structural damage in adult patients. Psoriatic arthritis: improves joint and skin symptoms, slowing disease progression. Severe rheumatoid arthritis: used as part of combination therapy to enhance therapeutic response.

Leflunomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea - Nausea - Alopecia - Rash - Elevated liver enzymes - Hypertension

Serious or Rare Side Effects: - Severe liver injury - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Bone marrow suppression leading to anemia or leukopenia - Interstitial lung disease

Before initiating therapy, several safety considerations should be observed.

Pregnancy: contraindicated; teratogenic risk mandates effective contraception. Liver function: baseline and periodic monitoring of hepatic enzymes is required. Blood pressure: monitor regularly as hypertension may develop. Infections: assess for active infections; avoid initiating therapy during uncontrolled infection. Immunosuppression: live vaccines should not be administered during treatment. Store at ambient temperature: keep below 25°C, in the original pack, protected from moisture.

Leflunomide can interact with several medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect; monitor INR closely. - Methotrexate: additive hepatotoxicity; concurrent use should be avoided. - Bile‑acid sequestrants (e.g., cholestyramine): reduce Leflunomide exposure, may require dose adjustment.

Moderate Interactions (Monitor Closely): - Azathioprine: enhanced immunosuppression; monitor blood counts. - Cyclosporine: potential increase in liver toxicity; regular liver function tests are advised.